OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Gibney on Selecting Between BRAF Inhibitor Regimens in Melanoma

November 2nd 2020

Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.

Dr. Schiffer on Factors to Consider for TKI Discontinuation in CML

November 2nd 2020

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC

October 30th 2020

Nilofer Saba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

Dr. Tap on the Rise of Precision Medicine in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma

October 30th 2020

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Dr. Ahn on the Identification of NTRK Alterations in CRC

October 30th 2020

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Dr. Atkins on the Expanding Role of Immunotherapy in Oncology

October 30th 2020

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma

October 30th 2020

William D. Tap, MD, discusses the importance of community and academic collaboration in sarcoma.

Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC

October 29th 2020

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Dr. Cohen on the Design on the SPEARHEAD-2 Trial in Head and Neck Cancer

October 29th 2020

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.

Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC

October 29th 2020

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Dr. Wolin on the Treatment Landscape of NETs

October 29th 2020

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

Dr. Goff on the Need to Identify Novel Targets in HCC

October 29th 2020

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer

October 29th 2020

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Dr. Azad on Third-Line Treatment Options in CRC

October 29th 2020

Nilofer Saba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC

October 28th 2020

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.

Dr. Hammers on Investigational Strategies to Inflame Tumors in RCC

October 28th 2020

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Dr. Luke on the Importance of BRAF in Melanoma

October 28th 2020

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma

October 28th 2020

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC

October 28th 2020

Benjamin P. Levy, MD, discusses the mechanism of action of telaglenastat in non–small cell lung cancer.